Onco-Circuit Addiction and Onco-Nutrient mTORC1 Signaling Vulnerability in a Model of Aggressive T Cell Malignancy
Xinxin WangiD, Andrew E. CornishiD, Mytrang Do, Julia S. BrunneriD, Ting-Wei HsuiD, Zijian Xu, Isha Malik, Chaucie Edwards, Kristelle J. CapistranoiD, Xian ZhangiD, Mark H. GinsbergiD, Lydia W.S. FinleyiD, Megan S. LimiD, Steven Michael HorwitziD, Ming O. LiiD
Abstract
How genetic lesions drive cell transformation and whether they can be circumvented without compromising function of non-transformed cells are enduring questions in oncology. Here we show that in mature T cells--in which physiologic clonal proliferation is a cardinal feature-- constitutive MYC transcription and Tsc1 loss in mice modeled aggressive human malignancy by reinforcing each others oncogenic programs. This cooperation was supported by MYC-induced large neutral amino acid transporter chaperone SLC3A2 and dietary leucine, which in synergy with Tsc1 deletion overstimulated mTORC1 to promote mitochondrial fitness and MYC protein overexpression in a positive feedback circuit. A low leucine diet was therapeutic even in late-stage disease but did not hinder T cell immunity to infectious challenge, nor impede T cell transformation driven by constitutive nutrient mTORC1 signaling via Depdc5 loss. Thus, mTORC1 signaling hypersensitivity to leucine as an onco-nutrient enables an onco-circuit, decoupling pathologic from physiologic utilization of nutrient acquisition pathways.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Glutamine-driven mTORC1 activity enforces glycolytic bias, hyperactivation and aberrant proliferation in T cells in chronic B-cell leukemia
Nienke B. Goedhart, Elena Camerini, … Helga Simon‐Molas·bioRxiv·Jun 10, 2026
- LARP1 integrates MYC and mTOR signaling to enable anabolic growth during tumor initiation
Pedro Fuentes, Flavia Iannizzotto, … Antonio Gentilella·Proceedings of the National Academy of SciencesPeer-reviewed·Jun 12, 2026
- TSC2 regulates tumor susceptibility to TRAIL-mediated T cell killing by orchestrating mTOR signaling
D. S. Peeper, C.-P. Lin, … N. L. Visser·bioRxiv·May 9, 2022
- Methionine metabolism and the NOP2 methyltransferase are essential for MYC-Driven liver tumorigenesis.
Sensen Lin, Charles A. Berdan, … Andrei Goga·bioRxiv·Jan 30, 2026
- Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and rewires the microenvironment toward an immune-suppressive state
Y. Tang, D. J. Kwiatkowski, E. P. Henske·bioRxiv·Jun 1, 2022
- Therapeutic targeting of ACLY in T-ALL in vivo
V. da Silva-Diz, A. Singh, … D. Herranz·bioRxiv·Mar 27, 2023